 The purpose of this study is to determine the efficacy, safety, tolerability, and pharmacokinetics PK of meropenem-vaborbactam compared to piperacillintazobactam for 7 to 14 days in the treatment of hospitalized adults who meet clinical, radiographic, and microbiological criteria for hospital-acquired bacterial pneumonia HABP or ventilator-associated bacterial pneumonia VABP. 